Head-To-Head Review: OKYO Pharma (NASDAQ:OKYO) vs. CG Oncology (NASDAQ:CGON)

OKYO Pharma (NASDAQ:OKYO) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Profitability

This table compares OKYO Pharma and CG Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
CG Oncology	-10,642.98%	-18.97%	-15.36%

Analyst Recommendations

This is a breakdown of current ratings for OKYO Pharma and CG Oncology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	0	0	1	0	3.00
CG Oncology	0	0	8	1	3.11

OKYO Pharma presently has a consensus target price of $7.00, indicating a potential upside of 542.20%. CG Oncology has a consensus target price of $65.14, indicating a potential upside of 130.84%. Given OKYO Pharma’s higher probable upside, equities analysts plainly believe OKYO Pharma is more favorable than CG Oncology.

Institutional & Insider Ownership

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares OKYO Pharma and CG Oncology”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$16.83 million	N/A	N/A
CG Oncology	$200,000.00	10,729.24	-$48.61 million	N/A	N/A

OKYO Pharma has higher earnings, but lower revenue than CG Oncology.

Summary

OKYO Pharma beats CG Oncology on 6 of the 11 factors compared between the two stocks.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.